ImmuCell CEO exercises options for 16,393 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ImmuCell Corp. (ICCC) President and CEO Paul Francis Olivier te Boekhorst exercised options on November 12, 2026, to acquire 16,393 common shares at $6.10 per share. Afterward, his reported direct common-stock position was 34,131 shares, and 57,884 shares remained subject to the option, which expires November 7, 2035. A correction note states that the beneficial-ownership total corrects the June 22, 2026 Form 4: the share-purchase count was correct, but total ownership was overstated by 47 shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Incentive Stock Options (Right to buy) F2, F3 | 16,393 | $0.00 | $0.00 |
| Exercise | Common Stock, par value $.10 per share F1 | 16,393 | $6.10 | $100K |
Footnotes (3)
- F1. Total beneficial ownership shown here reflects a correction in the amount previously reported June 22, 2026 on Form 4 (which correctly reported the number of shares purchases but overstated total ownership by 47 shares).
- F2. The stock option vests in three annual installments of 24.759 shares on the first, second and third anniversaries of the November 7, 2026 grant date. The first installment vested on November7, 2026.
- F3. Represents the number of shares remaining subject to the option following the reported exercise.
Key Figures
Key Terms
Incentive Stock Options technical
vests technical
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.